Brief Summary
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult patients who have the appropriate HLA-A2 tissuea group of cells that work together to perform a function marker and whose cancer is positive for PRAME.
Intervention / Treatment
- Drug: Brenetafusp
- Drug: Brenetafusp and pembrolizumab
- Drug: Brenetafusp and chemotherapya cancer treatment that uses drugs to kill or slow the growth of cancer cells, while minimising damage to healthy cells
- Drug: Brenetafusp and monoclonal antibodies and chemotherapy
- Drug: Brenetafusp and tebentafusp
- Drug: Brenetafusp and bevacizumab
- Drug: Brenetafusp and kinase inhibitors
Inclusion Criteria:
- ECOG PS 0 or 1
- HLA-A*02:01 positive
- PRAME positive tumor
- Relapsed from, refractory to, or intolerant of standard therapies; or, in combination with standard therapies
- If applicable, must agree to use highly effective contraception.